All recent publications

1. Periche PG, et al. Targeting Carbohydrate Mimetics of Tetrahydrofuran-Containing Acetogenins to Prostate Cancer. Molecules. 2023 Mar 23;28(7):2884. doi: 10.3390/molecules28072884

2. Bakht MK, et al. Landscape of prostate-specific membrane antigen heterogeneity and regulation in AR-positive and AR-negative metastatic prostate cancer. Nat Cancer. 2023 May;4(5):699-715. doi: 10.1038/s43018-023-00539-6

3. Martinez J, et al. Cyclotron vs generator-produced 68Ga PSMA: a single-institution, prospective clinical trial. Transl Oncol. 2023 Feb;28:101593. doi: 10.1016/j.tranon.2022.101593

4. Adilbay D, et al. Non-invasive diagnostic method to objectively measure olfaction and diagnose smell disorders by molecularly targeted fluorescent imaging agent. bioRxiv. 2022 Nov 29:2021.10.07.463532. Preprint. doi: 10.1101/2021.10.07.463532

5. Gonzalez Periche P, et al. Synthesis of carbohydrate analogues of the THF-acetogenin 4-deoxyannomontacin and their cytotoxicity against human prostate cancer cell lines. Carbohydr Res. 2022 Nov;521:108671. doi: 10.1016/j.carres.2022.108671

6. Demétrio de Souza França P, et al. Polyethylene Glycol 3350 (PEG 3350) as a Practical Vehicle for Rapid Reconstitution of PARPi-FL Formulations for Clinical Use. Mol Imaging Biol. 2023 Apr;25(2):294-302. doi: 10.1007/s11307-022-01756-8

7. Korsen JA, et al. Delta-like ligand 3-targeted radioimmunotherapy for neuroendocrine prostate cancer. Proc Natl Acad Sci U S A. 2022 Jul 5;119(27):e2203820119. doi: 10.1073/pnas.2203820119

8. Chakraborty G, et al. The Impact of PIK3R1 Mutations and Insulin-PI3K-Glycolytic Pathway Regulation in Prostate Cancer. Clin Cancer Res. 2022 Aug 15;28(16):3603-3617. doi: 10.1158/1078-0432.CCR-21-4272

9. Sharma S, et al. Synthesis of (124)I-labeled epichaperome probes and assessment in visualizing pathologic protein-protein interaction networks in tumor bearing mice. STAR Protoc. 2022 Apr 19;3(2):101318. doi: 10.1016/j.xpro.2022.101318

10. Russell J, et al. Analysis of capecitabine metabolites in conjunction with digital autoradiography in a murine model of pancreatic cancer suggests extensive drug penetration through the tumor. Pharmacol Res Perspect. 2022 Apr;10(2):e00898. doi: 10.1002/prp2.898

11. Nagle VL, et al. Noninvasive Imaging of CD4+ T Cells in Humanized Mice. Mol Cancer Ther. 2022 Apr 1;21(4):658-666. doi: 10.1158/1535-7163.MCT-21-0888

12. Korsen JA, et al. Molecular Imaging of Neuroendocrine Prostate Cancer by Targeting Delta-Like Ligand 3. J Nucl Med. 2022 Sep;63(9):1401-1407. doi: 10.2967/jnumed.121.263221

13. Tully KM, et al. Radioimmunotherapy Targeting Delta-like Ligand 3 in Small Cell Lung Cancer Exhibits Antitumor Efficacy with Low Toxicity. Clin Cancer Res. 2022 Apr 1;28(7):1391-1401. doi: 10.1158/1078-0432.CCR-21-1533

14. Joshi S, et al. Pharmacologically controlling protein-protein interactions through epichaperomes for therapeutic vulnerability in cancer. Commun Biol. 2021 Nov 25;4(1):1333. doi: 10.1038/s42003-021-02842-3

15. Saha N, et al. Inhibitory monoclonal antibody targeting ADAM17 expressed on cancer cells. Transl Oncol. 2022 Jan;15(1):101265. doi: 10.1016/j.tranon.2021.101265

16. Nie P, et al. Imaging of Cancer γ-Secretase Activity Using an Inhibitor-Based PET Probe. Clin Cancer Res. 2021 Nov 15;27(22):6145-6155. doi: 10.1158/1078-0432.CCR-21-0940

17. Henry KE, et al. ERK Inhibition Improves Anti-PD-L1 Immune Checkpoint Blockade in Preclinical Pancreatic Ductal Adenocarcinoma. Mol Cancer Ther. 2021 Oct;20(10):2026-2034. doi: 10.1158/1535-7163.MCT-20-1112

18. Bolaender A, et al. Chemical tools for epichaperome-mediated interactome dysfunctions of the central nervous system. Nat Commun. 2021 Aug 3;12(1):4669. doi: 10.1038/s41467-021-24821-2

19. Wilson T, et al. PARP-Targeted Auger Therapy in p53 Mutant Colon Cancer Xenograft Mouse Models. Mol Pharm. 2021 Sep 6;18(9):3418-3428. doi: 10.1021/acs.molpharmaceut.1c00323

20. Pirovano G, et al. Rapid detection of SARS-CoV-2 using a radiolabeled antibody. Nucl Med Biol. 2021 Jul-Aug;98-99:69-75. doi: 10.1016/j.nucmedbio.2021.05.002

21. Volpe A, et al. Applications of nuclear-based imaging in gene and cell therapy: probe considerations. Mol Ther Oncolytics. 2021 Feb 4;20:447-458. doi: 10.1016/j.omto.2021.01.017

22. Kalidindi TM, et al. A simple strategy to reduce the salivary gland and kidney uptake of PSMA-targeting small molecule radiopharmaceuticals. Eur J Nucl Med Mol Imaging. 2021 Jul;48(8):2642-2651. doi: 10.1007/s00259-020-05150-w

23. Harmsen S, et al. A dual-modal PET/near infrared fluorescent nanotag for long-term immune cell tracking. Biomaterials. 2021 Feb;269:120630. doi: 10.1016/j.biomaterials.2020.120630

24. Jhaveri KL, et al. Measuring Tumor Epichaperome Expression Using [(124)I] PU-H71 Positron Emission Tomography as a Biomarker of Response for PU-H71 Plus Nab-Paclitaxel in HER2-Negative Metastatic Breast Cancer. JCO Precis Oncol. 2020 Nov 17;4:PO.20.00273. doi: 10.1200/PO.20.00273

25. Cheal SM, et al. Alpha radioimmunotherapy using (225)Ac-proteus-DOTA for solid tumors - safety at curative doses. Theranostics. 2020 Sep 14;10(25):11359-11375. doi: 10.7150/thno.48810

26. Pillarsetty N, et al. Oncology-Inspired Treatment Options for COVID-19. J Nucl Med. 2020 Dec;61(12):1720-1723. doi: 10.2967/jnumed.120.249748

27. Russell J, et al. Predicting Gemcitabine Delivery by (18)F-FAC PET in Murine Models of Pancreatic Cancer. J Nucl Med. 2021 Feb;62(2):195-200. doi: 10.2967/jnumed.120.246926

28. Wilson TC, et al. Improved radiosynthesis of (123)I-MAPi, an auger theranostic agent. Int J Radiat Biol. 2023;99(1):70-76. doi: 10.1080/09553002.2020.1781283

29. Pratt EC, et al. Synthesis of the PET Tracer (124)I-Trametinib for MAPK/ERK Kinase Distribution and Resistance Monitoring. J Nucl Med. 2020 Dec;61(12):1845-1850. doi: 10.2967/jnumed.120.241901

30. Wilson TC, et al. A one-pot radiosynthesis of [(18) F]PARPi. J Labelled Comp Radiopharm. 2020 Jul;63(9):419-425. doi: 10.1002/jlcr.3847

31. Dunphy MPS, et al. First-in-Human Trial of Epichaperome-Targeted PET in Patients with Cancer. Clin Cancer Res. 2020 Oct 1;26(19):5178-5187. doi: 10.1158/1078-0432.CCR-19-3704

32. Fanchon LM, et al. Comparing the intra-tumoral distribution of Gemcitabine, 5-Fluorouracil, and Capecitabine in a murine model of pancreatic ductal adenocarcinoma. PLoS One. 2020 Apr 16;15(4):e0231745. doi: 10.1371/journal.pone.0231745

33. Inda MC, et al. The epichaperome is a mediator of toxic hippocampal stress and leads to protein connectivity-based dysfunction. Nat Commun. 2020 Jan 16;11(1):319. doi: 10.1038/s41467-019-14082-5

34. Pillarsetty N, et al. Paradigms for Precision Medicine in Epichaperome Cancer Therapy. Cancer Cell. 2019 Nov 11;36(5):559-573.e7. doi: 10.1016/j.ccell.2019.09.007

35. Gangangari KK, et al. Imaging Sigma-1 Receptor (S1R) Expression Using Iodine-124-Labeled 1-(4-Iodophenyl)-3-(2-adamantyl)guanidine ([(124)I]IPAG). Mol Imaging Biol. 2020 Apr;22(2):358-366. doi: 10.1007/s11307-019-01369-8

36. Sharma SK, et al. A rapid bead-based radioligand binding assay for the determination of target-binding fraction and quality control of radiopharmaceuticals. Nucl Med Biol. 2019 Apr;71:32-38. doi: 10.1016/j.nucmedbio.2019.04.005

37. Brand C, et al. Leveraging PET to image folate receptor α therapy of an antibody-drug conjugate. EJNMMI Res. 2018 Aug 28;8(1):87. doi: 10.1186/s13550-018-0437-x